Latest Breaking News On - Heinz wiendl - Page 2 : comparemela.com

Immunic, Inc (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript

Jessica Breu: Good morning and welcome to Immunic s Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.

Michael schumannHeinz wiendlLarry steinmanFred lublinPiper sandlerJoseph murrayDaniel vittJessica breuGlenn whaleyThomas smithYasmeen rahimiBob foxTom smithWorld health organizationStanford university school of medicineUniversity of munster

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesHella kohlhofLawrence steinmanSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurologyUniversity of muStanford university school of medicineNeurological sciences

EQS-News: Immunic, Inc : Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug s Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting

New yorkUnited statesPaula schwartzLawrence steinmanEdna kaplanHella kohlhofSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittJessica breuAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurology

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug s Neuroprotective Potential

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.

New yorkUnited statesPaula schwartzLawrence steinmanEdna kaplanHella kohlhofSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittJessica breuAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurology

EQS-News: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug s Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th.

New yorkUnited statesPaula schwartzLawrence steinmanEdna kaplanHella kohlhofSteinmanl epstein barrHeinz wiendlLarry steinmanFred lublinDaniel vittJessica breuAndreas muehlerFredd lublinInstitute of translational neurologyDepartment of neurology